Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01732913 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Yosemite) | terminated | Phase 3 | 295 | Gilead SciencesINDUSTRY | 19 | Nov 16, 2018 | clinicaltrials |
| NCT01732926 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Bridalveil) | terminated | Phase 3 | 475 | Gilead SciencesINDUSTRY |
| 15 |
| Nov 16, 2018 |
| clinicaltrials |
| NCT00002835 | Combination Chemotherapy in Treating Patients With Lymphoma | completed | Phase 3 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00002565 | Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma | completed | Phase 3 | 61 | M.D. Anderson Cancer CenterOTHER | 3 | Nov 14, 2018 | clinicaltrials |
| NCT03733327 | BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 20 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT00038090 | Thalidomide-Dexamethasone for Multiple Myeloma | completed | Phase 2 / Phase 3 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00038233 | Thalidomide for Multiple Myeloma | completed | Phase 3 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00038558 | Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy | completed | Phase 3 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00641095 | Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma(MCLPIII) | completed | Phase 2 / Phase 3 | 370 | University College, LondonOTHER | 2 | Oct 31, 2018 | clinicaltrials |
| NCT01305655 | Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL(NOPHOCPG2) | completed | Phase 3 | 47 | Nordic Society for Pediatric Hematology and OncologyOTHER | 5 | Sep 28, 2018 | clinicaltrials |
| NCT01010061 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT01998880 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT02053610 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT00332202 | PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin | completed | Phase 3 | 758 | Eli Lilly and CompanyINDUSTRY | 25 | Sep 10, 2018 | clinicaltrials |
| NCT02489500 | Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib(VelRand) | terminated | Phase 3 | 3 | Boston Medical CenterOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT03655145 | HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation(MacHaploMud) | unknown | Phase 3 | 344 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Aug 31, 2018 | clinicaltrials |
| NCT01908621 | Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients. | completed | Phase 3 | 90 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT03647072 | PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy | recruiting | Phase 3 | 60 | Sherief Abd-ElsalamOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT00135499 | R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma | terminated | Phase 3 | 138 | Lymphoma Study AssociationOTHER | 3 | Aug 23, 2018 | clinicaltrials |
| NCT03454945 | Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides | unknown | Phase 3 | 30 | Cairo UniversityOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT00718549 | A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) | completed | Phase 3 | 128 | Hoffmann-La RocheINDUSTRY | 2 | Aug 20, 2018 | clinicaltrials |
| NCT03623087 | SIMPLE Chemotherapy for NK Lymphoma/Leukaemia | unknown | Phase 3 | 68 | The University of Hong KongOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT00232934 | Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients | completed | Phase 3 | 400 | Gruppo Italiano per lo Studio del Mieloma MultiploOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT01482962 | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | completed | Phase 3 | 271 | Millennium Pharmaceuticals, Inc.INDUSTRY | 31 | Jul 31, 2018 | clinicaltrials |
| NCT01973387 | A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma | completed | Phase 3 | 160 | Janssen Research & Development, LLCINDUSTRY | 4 | Jul 24, 2018 | clinicaltrials |
| NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 487 | Millennium Pharmaceuticals, Inc.INDUSTRY | 29 | Jul 12, 2018 | clinicaltrials |
| NCT00056056 | Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides | terminated | Phase 3 | 93 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Jul 9, 2018 | clinicaltrials |
| NCT00566228 | Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma | completed | Phase 3 | 122 | Mayo ClinicOTHER | 1 | Jul 9, 2018 | clinicaltrials |
| NCT01098656 | Lenalidomide Maintenance Post-debulking in Advanced CTCL | terminated | Phase 3 | 21 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Jul 9, 2018 | clinicaltrials |
| NCT03564704 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | unknown | Phase 2 / Phase 3 | 80 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 21, 2018 | clinicaltrials |
| NCT03562169 | The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd) | recruiting | Phase 3 | 406 | University of LeedsOTHER | 1 | Jun 19, 2018 | clinicaltrials |
| NCT03553238 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | unknown | Phase 2 / Phase 3 | 70 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT03553537 | Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | unknown | Phase 3 | 100 | Southwest Hospital, ChinaOTHER | 0 | Jun 12, 2018 | clinicaltrials |
| NCT01554852 | Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients(Myeloma XI) | unknown | Phase 3 | 4,420 | University of LeedsOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT01200589 | Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy(HOMER) | terminated | Phase 3 | 438 | Novartis PharmaceuticalsINDUSTRY | 16 | May 16, 2018 | clinicaltrials |
| NCT00281892 | Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 97 | German CLL Study GroupOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT02359162 | Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage | terminated | Phase 3 | 50 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT02451774 | Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction(PTX-II) | unknown | Phase 2 / Phase 3 | 44 | Ramón Óscar González-Ramella, Ph.DOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT00921414 | Mantel Cell Lymphoma Efficacy of Rituximab Maintenance | completed | Phase 3 | 299 | French Innovative Leukemia OrganisationOTHER | 1 | Apr 27, 2018 | clinicaltrials |
| NCT02991638 | Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers | unknown | Phase 3 | 62 | The University of Hong KongOTHER | 1 | Apr 12, 2018 | clinicaltrials |
| NCT02155634 | Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma | withdrawn | Phase 3 | 0 | CelgeneINDUSTRY | 0 | Apr 10, 2018 | clinicaltrials |
| NCT03479918 | R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS) | unknown | Phase 3 | 80 | Elena N.ParovichnikovaNETWORK | 1 | Mar 27, 2018 | clinicaltrials |
| NCT02366663 | BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL(SPINOZA) | terminated | Phase 3 | 3 | City of Hope Medical CenterOTHER | 1 | Mar 12, 2018 | clinicaltrials |
| NCT01659099 | GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma(GAINED) | terminated | Phase 3 | 671 | The Lymphoma Academic Research OrganisationOTHER | 2 | Mar 7, 2018 | clinicaltrials |
| NCT01002248 | Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients | terminated | Phase 3 | 135 | AEterna ZentarisINDUSTRY | 9 | Feb 9, 2018 | clinicaltrials |
| NCT02354313 | Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients(MCL0208) | unknown | Phase 3 | 300 | Fondazione Italiana Linfomi - ETSOTHER | 2 | Feb 9, 2018 | clinicaltrials |
| NCT00784537 | High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients(HD0801) | completed | Phase 2 / Phase 3 | 520 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 8, 2018 | clinicaltrials |
| NCT00877006 | Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study | completed | Phase 3 | 447 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 7 | Feb 5, 2018 | clinicaltrials |
| NCT01724021 | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | completed | Phase 3 | 743 | Hoffmann-La RocheINDUSTRY | 32 | Jan 23, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Nov 16, 2018source: clinicaltrials